These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38282038)

  • 21. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.
    Bajgain KT; Badal S; Bajgain BB; Santana MJ
    Am J Infect Control; 2021 Feb; 49(2):238-246. PubMed ID: 32659414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New York.
    Kabarriti R; Brodin NP; Maron MI; Guha C; Kalnicki S; Garg MK; Racine AD
    JAMA Netw Open; 2020 Sep; 3(9):e2019795. PubMed ID: 32975574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities.
    Bienvenu LA; Noonan J; Wang X; Peter K
    Cardiovasc Res; 2020 Dec; 116(14):2197-2206. PubMed ID: 33063089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of association of comorbidities on COVID-19 outcomes: a machine learning approach.
    Arévalo-Lorido JC; Carretero-Gómez J; Casas-Rojo JM; Antón-Santos JM; Melero-Bermejo JA; López-Carmona MD; Palacios LC; Sanz-Cánovas J; Pesqueira-Fontán PM; de la Peña-Fernández AA; de la Sierra Alcántara NM; García-García GM; Torres Peña JD; Magallanes-Gamboa JO; Fernández-Madera-Martinez R; Fernández-Fernández J; Rubio-Rivas M; Maestro-de la Calle G; Cervilla-Muñoz E; Ramos-Martínez A; Méndez-Bailón M; Ramos-Rincón JM; Gómez-Huelgas R;
    Curr Med Res Opin; 2022 Apr; 38(4):501-510. PubMed ID: 35037799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimorbidity and SARS-CoV-2-Related Outcomes: Analysis of a Cohort of Italian Patients.
    Catalano A; Dansero L; Gilcrease W; Macciotta A; Saugo C; Manfredi L; Gnavi R; Strippoli E; Zengarini N; Caramello V; Costa G; Sacerdote C; Ricceri F
    JMIR Public Health Surveill; 2023 Feb; 9():e41404. PubMed ID: 36626821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology, Clinico-Pathological Characteristics, and Comorbidities of SARS-CoV-2-Infected Pakistani Patients.
    Omer S; Gondal MF; Usman M; Sarwar MB; Roman M; Khan A; Afzal N; Qaiser TA; Yasir M; Shahzad F; Tahir R; Ayub S; Akram J; Faizan RM; Naveed MA; Jahan S
    Front Cell Infect Microbiol; 2022; 12():800511. PubMed ID: 35755851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comorbidity genetic risk and pathways impact SARS-CoV-2 infection outcomes.
    Jaros RK; Fadason T; Cameron-Smith D; Golovina E; O'Sullivan JM
    Sci Rep; 2023 Jun; 13(1):9879. PubMed ID: 37336921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study.
    Xiong S; Liu L; Lin F; Shi J; Han L; Liu H; He L; Jiang Q; Wang Z; Fu W; Li Z; Lu Q; Chen Z; Ding S
    BMC Infect Dis; 2020 Oct; 20(1):787. PubMed ID: 33092539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy.
    Preskorn SH
    J Psychiatr Pract; 2020 May; 26(3):219-227. PubMed ID: 32421292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring disparities and novel insights into metabolic and cardiovascular comorbidities among COVID-19 patients in Mexico.
    López-Cuevas JA; Martínez-García M; Hernández-Lemus E; de Anda-Jáuregui G
    Front Public Health; 2023; 11():1270404. PubMed ID: 37927854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19: a review on SARS-CoV-2 origin, epidemiology, virology, clinical manifestations and complications with special emphasis on adverse outcome in Bhopal Gas Tragedy survivor.
    Malviya A; Ahirwar AK; Chandra Tripathi S; Asia P; Gopal N; Kaim K
    Horm Mol Biol Clin Investig; 2021 Feb; 42(1):63-68. PubMed ID: 33600673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities.
    Arisan ED; Dart A; Grant GH; Arisan S; Cuhadaroglu S; Lange S; Uysal-Onganer P
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32512929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology.
    Suárez-Reyes A; Villegas-Valverde CA
    MEDICC Rev; 2021 Apr; 23(2):42. PubMed ID: 33974614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New York Inner City Hospital COVID-19 Experience and Current Data: Retrospective Analysis at the Epicenter of the American Coronavirus Outbreak.
    Mani VR; Kalabin A; Valdivieso SC; Murray-Ramcharan M; Donaldson B
    J Med Internet Res; 2020 Sep; 22(9):e20548. PubMed ID: 32540837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis.
    Mahumud RA; Kamara JK; Renzaho AMN
    Infection; 2020 Dec; 48(6):813-833. PubMed ID: 32813220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study.
    Abayomi A; Osibogun A; Kanma-Okafor O; Idris J; Bowale A; Wright O; Adebayo B; Balogun M; Ogboye S; Adeseun R; Abdus-Salam I; Mutiu B; Saka B; Lajide D; Yenyi S; Agbolagorite R; Onasanya O; Erinosho E; Obasanya J; Adejumo O; Adesola S; Oshodi Y; Akase IE; Ogunbiyi S; Omosun A; Erinoso F; Abdur-Razzaq H; Osa N; Akinroye K
    Glob Health Res Policy; 2021 Jul; 6(1):26. PubMed ID: 34325747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.
    Ahmed S; Gasparyan AY; Zimba O
    Rheumatol Int; 2021 Feb; 41(2):243-256. PubMed ID: 33388969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study.
    Jassat W; Cohen C; Tempia S; Masha M; Goldstein S; Kufa T; Murangandi P; Savulescu D; Walaza S; Bam JL; Davies MA; Prozesky HW; Naude J; Mnguni AT; Lawrence CA; Mathema HT; Zamparini J; Black J; Mehta R; Parker A; Chikobvu P; Dawood H; Muvhango N; Strydom R; Adelekan T; Mdlovu B; Moodley N; Namavhandu EL; Rheeder P; Venturas J; Magula N; Blumberg L;
    Lancet HIV; 2021 Sep; 8(9):e554-e567. PubMed ID: 34363789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach.
    Yousefi H; Poursheikhani A; Bahmanpour Z; Vatanmakanian M; Taheri M; Mashouri L; Alahari SK
    Biomed Pharmacother; 2020 Oct; 130():110548. PubMed ID: 33475497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.